NIPPON CHEMIPHAR CO., LTD. Logo

NIPPON CHEMIPHAR CO., LTD.

Develops, manufactures, and sells pharmaceuticals and diagnostic agents.

4539 | T

Overview

Corporate Details

ISIN(s):
JP3701600003
LEI:
Country:
Japan
Address:
千代田区岩本町二丁目2番3号

Description

NIPPON CHEMIPHAR CO., LTD. is a healthcare company engaged in the research, development, manufacture, and sale of ethical pharmaceuticals, diagnostic agents, and health-related products. The company's business focuses on three core areas: a quality-driven generic drug business, the development of innovative products based on core technologies in the field of allergy, and the creation of new drugs from proprietary technologies, including alkalization therapy. Its product portfolio addresses therapeutic areas such as lifestyle-related and allergic diseases. In the diagnostics sector, the company provides clinical testing kits and agents to support disease management and prevention.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 02:32
確認書
Japanese 8.7 KB
2025-11-13 02:32
半期報告書-第94期(2025/04/01-2026/03/31)
Japanese 221.2 KB
2025-06-20 03:58
臨時報告書
Japanese 30.9 KB
2025-06-20 03:57
内部統制報告書-第93期(2024/04/01-2025/03/31)
Japanese 23.8 KB
2025-06-20 03:57
確認書
Japanese 8.6 KB
2025-06-20 03:56
有価証券報告書-第93期(2024/04/01-2025/03/31)
Japanese 1.2 MB
2024-11-13 01:21
半期報告書-第93期(2024/04/01-2025/03/31)
Japanese 223.1 KB
2024-11-13 01:21
確認書
Japanese 8.7 KB
2024-06-24 08:03
臨時報告書
Japanese 18.7 KB
2024-06-24 03:28
臨時報告書
Japanese 25.6 KB
2024-06-24 03:27
確認書
Japanese 8.6 KB
2024-06-24 03:26
内部統制報告書-第92期(2023/04/01-2024/03/31)
Japanese 23.2 KB
2024-06-24 03:24
有価証券報告書-第92期(2023/04/01-2024/03/31)
Japanese 1.2 MB
2024-02-13 04:31
確認書
Japanese 8.7 KB
2024-02-13 04:30
四半期報告書-第92期第3四半期(2023/10/01-2023/12/31)
Japanese 230.5 KB

Automate Your Workflow. Get a real-time feed of all NIPPON CHEMIPHAR CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NIPPON CHEMIPHAR CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NIPPON CHEMIPHAR CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.